Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

SAVE-MORE
  NCT04680949		 RCTanakinraplaceboCOVID 19 hospitalizedlow
412/194 conclusif
  • suggested 55 % decrease in deaths with a high degree of certainty due to low risk of bias
  • demonstrated 64 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias

COVID-19 mild to moderate meta-analysis

CORIMUNO-ANA-1
  NCT04341584		 RCTanakinracontrolCOVID-19 mild to moderatesome concern
59/57 inconclusive
    LIVE-AIR (Temesgen)
          NCT04351152    		 RCTlenzilumabplaceboCOVID-19 mild to moderatesome concern
    		261/259 conclusif
    • demonstrated 35 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    Amra
          IRCT20170207032444N3    		 RCTthalidomide standard of careCOVID-19 severe or criticallyhigh
    		30/30 inconclusive
      Kumar
              CTRI/2020/05/024959      		 RCTitolizumabstandard of careCOVID-19 severe or criticallyhigh
      		22/10 inconclusive
        CAN-COVID
                  NCT04362813        		 RCTcanakinumabplaceboCOVID-19 severe or criticallysome concern
        		227/227 inconclusive
        • inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons